Medicines for Europe

Looking forward to seeing you in 2025 at our events! Happy holidays! https://lnkd.in/egjvsPm2 The 3rd Bioequivalence Conference is organised with the support of the IGBA - International Generic and Biosimilar medicines Association! Thank you IGBA! #BIOEQ25 #RAC25 #BIOS25 #LAC25 #AccessforAll #MedsforEU25 #Generics #Genericmedicines #Biosimilars #Bioequivalence Medicines for Europe, Adrian van den Hoven, Beata Stepniewska, Indiana Castro Alonso, Beatriz S., Liana Petrosova, Loreleï L., Raluca Radu, Julie Marechal-Jamil, Mina Grguri, Sergio Napolitano, Giuliana Pennisi, Cristina Romagnoli, Trudy Beks, Erika Zavan, Kate O'Regan

🎄 As the holiday season approaches, Medicines for Europe wishes you and your families a joyful and restful time. This year, in response to ongoing global crises, we have chosen to donate to International Health Partners and Direct Relief to support their essential work in delivering medicines and health supplies to vulnerable and disaster-hit communities. ➡️ Learn more about their incredible work at buff.ly/3B5h1V9 and buff.ly/2KvAK1r. We look forward to the new year, focused on improving patient access to medicines and advancing healthcare goals! 🤝 #Access4All #EUCriticalHealth

📢 Exciting News! We are happy to announce that our member and partner, the Portuguese Association of Generic and Biosimilar Medicines (APOGEN), has evolved into EQUALMED - Associação Portuguesa de Medicamentos pela Equidade em Saúde. #EQUALMED now represents value added medicines alongside generics and biosimilars - a timely response to the evolving needs of both national and global healthcare markets.🌍 🤝 Let's keep working together to improve patient access to essential and #CriticalMeds, delivering better healthcare outcomes in Portugal and beyond!

📢 Save your spot for the next 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐀𝐟𝐟𝐚𝐢𝐫𝐬 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞, #RAC25! #RAC25 will bring together key stakeholders, including regulators, industry experts and EU officials, to analyse the challenges and opportunities ahead with the revision of the EU pharmaceutical legislation. Join us in Amsterdam on 27-28 February 2025! 📅 ➡️ Register here: https://buff.ly/4fbzhKj Trudy Beks Cristina Romagnoli Lucia Romagnoli

📢 Save the date for the next 𝗕𝗶𝗼𝗲𝗾𝘂𝗶𝘃𝗮𝗹𝗲𝗻𝗰𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲, #BIOEQ25!  The #bioequivalence landscape is evolving with key developments in guidelines and global regulatory harmonisation. Join us and international experts for discussions on the future of bioequivalence. 📅 26 February, 2025   📍 Hilton Amsterdam Airport Schiphol   Don’t miss this opportunity! ➡️ Save your spot now: https://buff.ly/3OMW98t   ➡️ Check out the programme: https://buff.ly/4iC1VXY Trudy Beks Cristina Romagnoli Lucia Romagnoli IGBA - International Generic and Biosimilar medicines Association

📢 As partners of REMEDi4ALL, we are excited to announce that the registration for #iDR25, the International Drug Repurposing Conference, is open! Join key opinion leaders from research, patient communities, funders, regulators and the private sector to unlock the potential of #MedsRepurposing for patient benefits. 🎯 #MedsRepurposing is crucial for advancing effective treatment options and provide innovative solutions for healthcare systems. Secure your spot for May 7 and 8, 2025, in Amsterdam and join iDR25 at remedi4all.org! #REMEDi4ALL #MedsRepurposing

Thank you Samsung Bioepis for being our silver sponsor at the #Biosimilar Medicines Conference on 3-4 April 2025, Amsterdam! Register on https://lnkd.in/dUsxCBBf Hotel booking form ➡️ https://lnkd.in/eSDruYVt More info ➡️ https://lnkd.in/dsVJNVTq #BIOS25 #Biosimilars #biosimilarmedicines Medicines for Europe, Adrian van den Hoven, Julie Marechal-Jamil, Mina Grguri, Trudy Beks, Cristina Romagnoli, Kate O'Regan, Erika Zavan Samsung Bioepis, Gillian Woollett, Antonio Rito, Remco de Haas

📌 Today, we held our Board and General Assembly meeting to recap the progress made in 2024 regarding medicines security and patient access to off-patent medicines.   Together, we discussed key achievements in generic, biosimilar and value added medicines, as well as outlined priorities for 2025 to continue making off-patent medicines an integral part of the solution for strengthening our healthcare systems. 📅   Let's keep working to enhance patient access to essential and #CriticalMeds, streamline access to #BiosimilarMedicines and advance the development of #ValueAddedMedicines.    🙌 Big thanks to all our members and national associations for their continued support!    #EUCriticalHealth #Access4All

🟣 #VAMWeek 2024 wraps up today! James Burt, Chair of our #ValueAddedMeds Sector Group, highlights the importance of encouraging more tolerable formats for patient treatment. #ValueAddedMedicines create cost-saving pathways that reduce hospital admissions and support physicians. Let’s work together to establish a fit-for-purpose regulatory framework that makes #MedRepurposing a reality and expands patient access. 🎯 Thank you for following #VAMWeek 2024! 🔁 ➡️ Read more in our White Paper: https://buff.ly/4hTHwxv Euractiv

We're at the forefront of the value-added medicine drive. With VAM Week coming to a close, make sure you stay up to date with all the latest news and updates on value-added medicines. Head to our value-added medicines hub page for our thought leadership articles, infographics, and case studies. https://bit.ly/4fRN5KO #VAMWeek